Physician profile
David A High
NPI 1972554400
$7,137.17
in general payments reported to CMS, 2019-2025
35 companies · $1,467 in 2025
The $1,467 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $885 · 2020: $521 · 2021: $872 · 2022: $726 · 2023: $1,113 · 2024: $1,552 · 2025: $1,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,933 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,932.63 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,183.14 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,137.89 | 2019-2025 | |
| Lilly USA, LLC | $826.27 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $549.54 | 2020-2025 | Tremfya |
| Leo Pharma INC. | $460.49 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $333.28 | 2022-2025 | Sotyktu |
| Ucb, INC. | $332.17 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $278.38 | 2020-2025 | |
| Dermavant Sciences, INC. | $233.03 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $226.20 | 2019-2025 | Winlevi |
| Pfizer INC. | $190.32 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $178.67 | 2019-2025 | Libtayo, Dupixent |
| Amgen INC. | $127.68 | 2020-2025 | Otezla |
| Galderma Laboratories, L.P. | $122.30 | 2019-2025 | Nemluvio, Dysport |
| Genentech USA, INC. | $121.51 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $84.13 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $82.54 | 2019-2021 | |
| Organon LLC | $78.74 | 2023-2025 | Hadlima, Vtama |
| Sebela Pharmaceuticals INC. | $76.39 | 2022-2023 | Naftin |
| Incyte Corporation | $68.48 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $54.01 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $45.37 | 2023-2025 | Zoryve |
| Epi Health, LLC | $43.53 | 2019-2022 | |
| Celgene Corporation | $42.57 | 2019 | |
| Journey Medical Corporation | $41.15 | 2021-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $37.79 | 2020-2022 | |
| Dermira, INC. | $30.41 | 2019-2020 | |
| Glaxosmithkline, LLC. | $27.12 | 2019 | |
| Glenmark Therapeutics INC. | $27.00 | 2019 | |
| Botanix Sb INC | $18.35 | 2025 | Sofdra |
| Genentech, INC. | $17.99 | 2023 | Erivedge |
| Verrica Pharmaceuticals INC. | $16.58 | 2024 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.11 | 2024 | Spevigo |
| Sandoz INC. | $14.61 | 2023 | Hyrimoz |
| Kyowa Kirin, INC. | $14.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David High listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.